智通财经APP讯，朝聚眼科(02219)发布公告，于2025年11月19日，该公司斥资30.78万港元回购12万股 股份，每股回购价格为2.55-2.58港元。 ...

格隆汇11月19日丨朝聚眼科(02219.HK)公告，11月19日耗资30.8万港元回购12万股。 ...

Group 1: Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 3.272 billion yuan, a year-on-year increase of 2.83% [1] - The net profit attributable to shareholders reached 434 million yuan, reflecting a year-on-year increase of 3.04% [1] - For the third quarter alone, the operating revenue was 1.133 billion yuan, showing a slight year-on-year growth of 0.13%, while the net profit attributable to shareholders decreased by 2.37% to 152 million yuan [1] Group 2: Dividend Distribution - The company plans to distribute a cash dividend of 0.9 yuan (including tax) for every 10 shares, totaling 749.2 million yuan, based on the number of shares after deducting the repurchased shares of 83.2 million [1] Group 3: Cost and Margin Analysis - The gross profit margin for the first three quarters of 2025 was 45.03%, a decrease of 1.00 percentage point year-on-year [1] - The selling expense ratio was 13.21%, down by 0.94 percentage points year-on-year, while the management expense ratio was 11.49%, a decrease of 0.08 percentage points [1] - The financial expense ratio increased by 0.24 percentage points to 1.03%, primarily due to reduced bank interest income from investing temporarily idle funds in financial products [1] Group 4: Strategic Development - The company is leveraging its "dual top-tier" advantage to establish a nationwide chain operation service system, focusing on both organic growth and external acquisitions [2] - In 2024, the company successfully acquired Chengdu Aidi Eye Hospital, becoming a large medical chain group with "dual top-tier" eye hospitals [2] - The company has identified 24 key investment provinces in China to build an ophthalmic medical service network through self-construction or acquisition [2] Group 5: Technological Advancement - The company introduced the new Zeiss SMILE pro technology for minimally invasive surgery, completing 2,000 SMILE pro surgeries by September 25, 2025, making it the first single hospital globally to reach this milestone in such a short time [2] Group 6: Revenue and Profit Forecast - The company forecasts operating revenues of 4.206 billion yuan, 4.697 billion yuan, and 5.239 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.4%, 11.7%, and 11.5% [2] - The net profit attributable to shareholders is expected to be 499 million yuan, 577 million yuan, and 661 million yuan for the same years, with growth rates of 16.4%, 15.6%, and 14.5% [2]

Core Viewpoint - The company, Aier Eye Hospital, emphasizes its first-mover advantage and comprehensive capabilities in providing multi-level ophthalmic medical services to all age groups, adapting to the changing spectrum of eye diseases and the growing demand due to an aging population [1] Group 1 - The company has opened presbyopia clinics and diabetic retinopathy clinics in multiple locations to address the increasing needs of the elderly population [1] - A multidisciplinary team (MDT) for presbyopia has been established to offer suitable visual solutions for the middle-aged and elderly demographic [1] - The potential demand for ophthalmic medical services in China is significant, and the company remains focused on its core business while enhancing its medical service capabilities through global advantages [1]

Core Viewpoint - 朝聚眼科 (02219) announced a share buyback plan, reflecting confidence in its business outlook and aiming to create value for shareholders [1] Group 1: Share Buyback Announcement - The company plans to repurchase up to HKD 50 million worth of its shares starting from November 17, 2025 [1] - This decision is based on the approval from shareholders at the annual general meeting held on June 6, 2025 [1] - The board may increase the maximum repurchase amount depending on market conditions and will announce any changes in accordance with listing rules [1] Group 2: Market Reaction - Following the announcement, the stock price of 朝聚眼科 rose by 4.07%, reaching HKD 2.56, with a trading volume of HKD 1.3851 million [1]

智通财经APP获悉，朝聚眼科(02219)涨超4%，截至发稿，涨4.07%，报2.56港元，成交额138.51万港 元。 消息面上，朝聚眼科发布公告，于2025年11月17日，董事会已决议根据公司股东于2025年6月6日举行的 股东周年大会上批准的股份购回授权及(如适用)其后股东不时批准的任何更新或重新订立的股份购回授 权，自2025年11月17日起不时于公开市场购回最多价值5000万港元的公司股份。 公司认为，进行股份购回可展示公司对自身业务展望及前景充满信心，且最终将会为公司带来裨益及为 其股东创造价值。根据市况，董事会可不时增加股份购回授权项下的最高购买总额。倘董事会决定增加 最高购回金额，公司将于必要时根据上市规则作出及时公告。 ...

Core Viewpoint - Several listed companies in China have announced dividend plans, indicating a trend of increasing shareholder returns and stable cash distributions [1][2][4]. Group 1: Dividend Announcements - Huillong Co. plans to distribute a cash dividend of 0.5 yuan per 10 shares, while Changgao Electric New plans to distribute 0.3 yuan per 10 shares [1]. - Aier Eye Hospital is set to distribute a total cash dividend of 7.44 billion yuan, with a dividend of 0.8 yuan per 10 shares [2]. - Midea Group has implemented a cash dividend of 5 yuan per 10 shares, totaling approximately 3.448 billion yuan [2]. Group 2: Company Performance and Dividends - Aier Eye Hospital reported a net profit of 3.11474 billion yuan, with a year-on-year net profit growth rate of -9.76% [2]. - Meihua Co. plans to distribute a cash dividend of 0.37 yuan per 10 shares, totaling approximately 12.55 million yuan, with a net profit of 128.6079 million yuan and a year-on-year growth rate of -10.66% [3]. - Changgao Electric New reported a net profit of 202.7069 million yuan and plans to distribute a cash dividend of 0.30 yuan per 10 shares, totaling approximately 18.61 million yuan [3]. Group 3: Industry Insights - Analysts suggest that stable dividend expectations can enhance company value and benefit investors, contributing to the stability of the capital market [4].

格隆汇11月18日丨朝聚眼科(02219.HK)发布公告，2025年11月17日，董事会已决议根据股份购回授权， 自2025年11月17日起不时于公开市场购回最多价值5000万港元的公司股份。 ...

Core Insights - The event organized by Shenzhen Stock Exchange aimed to deepen investors' understanding of Aier Eye Hospital's (300015) listed company status and its role in the ophthalmology sector [1] Group 1: Company Overview - Aier Eye Hospital maintains international synchronization and domestic leadership in refractive technology, offering a wide range of surgical procedures that are continuously upgraded [2] - The company emphasizes personalized medical services based on the principle that "the suitable is the best," leading to increased patient recognition of advanced techniques like "All Light Plastic," "All-Femto 4.0," and "All-Femto Pro" [2] Group 2: Business Development - Aier's business structure optimization has resulted in a steady increase in average pricing, demonstrating effective measures against market saturation [2] - The company's vision care business has developed a comprehensive system from prevention to treatment, enhancing its core competitiveness through an integrated medical education and research platform [2] Group 3: Market Expansion - Investors are particularly interested in Aier's international expansion, with the company acknowledging the vast potential of the overseas ophthalmology market [2] - Aier plans to pursue internationalization more actively and cautiously, focusing on healthy growth of existing overseas institutions while enhancing its medical network in surrounding regions [2]

Core Viewpoint - The company, Aier Eye Hospital Group, emphasizes its commitment to maintaining technological advancement in response to investor inquiries [1] Summary by Relevant Categories Company Developments - Aier Eye Hospital Group is closely monitoring new developments in the industry [1] - The company is dedicated to sustaining its technological leadership [1]